Marker of T-cell activation is elevated in refractory Kawasaki disease

Pediatrics International

Volumn 52, Issue 5, 2010, Pages 785-789

  Suzuki, Hiroyuki ^a   Suenaga, Tomohiro ^a   Takeuchi, Takashi ^a   Shibuta, Shoichi ^b   Yoshikawa, Norishige ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b Kinan Hospital   (Japan)

Author keywords

Kawasaki disease; resistant to intravenous immunoglobulin; T cell activation

Indexed keywords

ACETYLSALICYLIC ACID; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6;

ARTICLE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; DISEASE SEVERITY; ENZYME IMMUNOASSAY; HUMAN; INFLAMMATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; INTERLEUKIN-2; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 77957348033     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2010.03163.x     Document Type: Article

References (23)

1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of fingers and toes in children: Clinical observation of 50 cases. Jpn. J. Allergol. 1967 16 : 178 222.
2. Nakamura Y, Yashiro M, Uehara R, Oki I, Kayaba K, Yanagawa H. Epidemiologic features of Kawasaki disease in Japan: Results from the nationwide survey in 2005-2006. J. Epidemiol. 2008 18 : 167 172.
3. Ueno Y, Takano N, Kanegane H et al. The acute phase nature of interleukin 6: Studies in Kawasaki disease and other febrile illness. Clin. Exp. Immunol. 1989 76 : 337 342.
4. Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin. Immunol. Immunopathol. 1990 56 : 29 36.
5. Lang BA, Silverman ED, Laxer RM, Rose V, Nelson DL, Rubin LA. Serum-soluble interleukin-2 receptor levels in Kawasaki disease. J. Pediatr. 1990 116 : 592 596.
6. Furukawa S, Matsubara T, Yone K, Hirano Y, Okumura K, Yabuta K. Kawasaki disease differs from anaphylactoid purpura and measles with regard to tumor necrosis factor-alpha and interleukin 6 in serum. Eur. J. Pediatr. 1992 151 : 44 7.
7. Raman V, Kim J, Sharkey A, Chatila T. Response of refractory Kawasaki disease to pulse steroid and cyclosporine A therapy. Pediatr. Infect. Dis. J. 2001 20 : 635 637.
8. Onouchi Y, Gunji T, Burns JC et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat. Genet 2008 40 : 35 42.
9. de Inocencio J, Hirsch R. The role of T cells in Kawasaki disease. Crit. Rev. Immunol. 1995 15 (3-4 349 357.
10. Matsubara T, Anwar R, Fujiwara M, Ichiyama T, Furukawa S. CTLA-4 (CD152) expression in peripheral blood T cells in Kawasaki disease. Clin. Exp. Immunol. 2003 132 : 169 173.
11. Yoshioka T, Matsutani T, Toyosaki-Maeda T et al. Relation of streptococcal pyrogenic exotoxin C as a causative superantigen for Kawasaki disease. Pediatr. Res. 2003 53 : 403 410.
12. Kimura J, Takada H, Nomura A et al. Th1 and Th2 cytokine production is suppressed at the level of transcriptional regulation in Kawasaki disease. Clin. Exp. Immunol. 2004 137 : 444 449.
13. Brogan PA, Shah V, Clarke LA, Dillon MJ, Klein N. T cell activation profiles in Kawasaki syndrome. Clin. Exp. Immunol. 2008 151 : 267 274.
14. Witkowska AM. On the role of sIL-2R measurements in rheumatoid arthritis and cancers. Mediators Inflamm. 2005 14 : 121 130.
15. Nishimoto N, Kishimoto T, Yoshizaki K. Anticytokine therapy in autoimmune disease. Intern. Med. 1999 38 : 178 182.
16. Noma T, Mizuta T, Rosen A, Hirano T, Kishimoto T, Honjo T. Enhancement of the interleukin-2 receptor expression on T cells by multiple B-lymphotropic lymphokines. Immunol. Lett. 1987 15 : 249 253.
17. Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF-2 functions as killer helper factor in the in vivo induction of cytotoxic T cells. J. Immunol. 1988 141 : 1543 1549.
18. th edn. Japanese Kawasaki Disease Research Committee, Tokyo, 2002.
19. Abe J, Jibiki T, Noma S, Nakajima T, Saito H, Terai M. Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J. Immunol. 2005 174 : 5837 5845.
20. Popper SJ, Shimizu C, Shike H et al. Gene-expression patterns reveal underlying biological processes in Kawasaki disease. Genome Biol. 2007 8 (12 R261.
21. Suenaga T, Suzuki H, Takeuchi T, Shibuta S, Yoshikawa N. Detection of multiple superantigen genes in stools of patients with Kawasaki disease. J. Pediatr. 2009 155 : 266 270.
22. Gotoh Y, Okamoto Y, Uemura O et al. Determination of age-related changes in human soluble interleukin 2 receptor in body fluids of normal subjects as a control value against disease states. Clin. Chim. Acta 1999 289 : 89 97.
23. Gilad R, Lampl Y, Eshel Y, Barak V, Sarova-Pinhas I. Cerebrospinal fluid soluble interleukin-2 receptor in cerebral lupus. Br. J. Rheumatol. 1997 36 : 190 193.